YNT-185

Research use only, not for human use.

YNT-185 is a nonpeptide, selective agonist of the orexin type-2 receptor (OX2R), with EC50 values of 0.028 μM for OX2R and 2.75 μM for OX1R.

YNT-185 is a nonpeptide, selective orexin type-2 receptor (OX2R) agonist, with EC50s of 0.028 and 2.75 μM for OX2R and OX1R, respectively. YNT-185 ameliorates narcolepsy-cataplexy symptoms in mouse models.

——

YNT-185 (20-40 mg/kg; i.p.) increases wakefulness in mice.YNT-185 (300 nmol; i.c.v.) significantly increases wake time for 3 hours in a dose-dependent manner, accompanied by a decrease in NREM sleep time, in wild-type mice but not in OXRDKO mice.Animal Model:Male wild-type C57BL/6J mice Dosage:20, 40 mg/kg Administration:I.p.Result:Wake time was also significantly increased.

——

Others

Other Targets

OX Receptor

——

——

1804978-81-1

615.74

C33H37N5O5S

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (162.41 mM; Ultrasonic )

S(NC1=CC(NCCNC(=O)C2=C(N(C)C)C=CC=C2)=CC=C1)(=O)(=O)C3=C(OC)C=CC(=C3)C4=CC(C(N(C)C)=O)=CC=C4

——

(-20℃)

With Ice Pack

≥ 2 years